Latest News

InflaRX raises US$55m in Series D round

InflaRX lead candidate (blue) binding complement factor C% (red). © InflaRx


by tg

German infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC  to finance its clinical programmes with its lead asset IFX-1.

According to the company, the transaction consists of a US$30m capital increase and a US$25m secondary share purchase. Proceeds from the capital increase will be used to advance Phase IIb development of InflaRx's lead IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance non disclosed preclinical development of pipeline products.

In July 2017, InflaRx published results from a Phase IIa open label trial in patients suffering from the autoimmune skin disease Hidradenitis Suppurativa, which demonstrated the disease modifying activity of IFX-1. After having turned away from clinical testing of the compound in the investor-averse field of sepsis, for which no approved treatment exists, InflaRx has built a robust pipeline in different inflammatory/autoimmune indications.

Switzerland paves the way for genome editing

Following in the footsteps of the UK, Switzerland wants to exempt genome editing and targeted mutagenesis in plant breeding from the Swiss Genetic...

TWB partners with Processium and Syngulon

With the new partnerships, TWB optimizes the support of projects led by hosted startups and industry partners. Processium is  specialised in...

Enzymaster raises $45m in Series C round

The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh...

Biotalys’ first proteinbased biocontrol shows up in vineyards

Biotalys, the  agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

Engimmune Therapeutics raises CHF15.5m in seed financing

Pureos Bioventures and Novo Holdings co-led the financing of Engimmune Therapeutics, a spin-off from the research group of Prof. Sai Reddy at the...

Evotec and BMS intensify R&D on protein degraders

$50m for London CHARM Therapeutics for deep minded folding expertise

London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...